S492
Clinical - Gynaecological
ESTRO 2026
Purpose/Objective: Background: Standard treatment for primary vaginal cancer consists in combination of external beam radiotherapy (EBRT) and brachytherapy (BT), with or without chemotherapy. Due to the rarity of this disease, most treatment recommendations are extrapolated from cervical cancer protocols, leading to variability in clinical approaches across centers worldwide. Purpose: To evaluate local tumor control, recurrence rates, survival outcome, radiation dose, and severe adverse events in women with primary vaginal cancer. Material/Methods: Method: This retrospective study included patients with primary vaginal cancer who received definitive radiotherapy, with or without chemotherapy, between 1978 and 2018 at Örebro University Hospital, Sweden. The study was approved by the Regional Ethical Review Board in Uppsala. Results: Results: Seventy-one patients met the inclusion criteria. The median age was 71 years (37 -94). FIGO stage distribution was as follows: stage I (25.3%), stage II (47.9%), stage III (12.6 %), stage IV (11.2%), stage X (2.8%). Squamous cell carcinoma accounted for 84.5% of cases. Most patients (69%) were treated with a combination of EBRT and BT. Median follow-up time was five years, the recurrence rate was 25%. Severe adverse effects were reported in 6% of patients. Conclusion: No significant correlations were found between different radiation dose and recurrence or cumulative survival, nor between FIGO stage and recurrence. Primary vaginal cancer remains a therapeutic challenge for the health care professionals involved in the treatment and care of affected patients. References: 1. Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1(Suppl 1):19-27.2. Kirschner AN, Kidd
EA, Dewees T, Perkins SM. Treatment approach and outcomes of vaginal melanoma. Int J Gynecol Cancer. 2013;23(8):1484-9.3.
Tran PT, Su
Z, Lee P, Lavori P, Husain A, Teng N, et al. Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol. 2007;105(3):641-94. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6. Keywords: Vaginal cancer, brachytherapy, chemoradiation. Improved target coverage for cervical cancer regional hyperthermia using HyperPlan® for the clinical BSD2000 system: a simulation study Siddharth Arora, Michel Benjamin, Anna Chiara Giovannelli, Aigerim Kadyrova, Moritz V. Scharr, Dorothea H. Kopp, Daniel Zips, Jacek Nadobny, Julia Bauer, Pirus Ghadjar Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany Digital Poster 5049 Purpose/Objective: Hyperthermia treatment planning is essential for improving treatment quality and consistency. This study presents a simulation- based evaluation of the HyperPlan® treatment planning system for regional hyperthermia in cervical cancer. Material/Methods: Ten patients with locally advanced cervical
cancer who underwent combined radiochemotherapy and regional
hyperthermia between 2016 and 2023 were retrospectively analyzed. Patient-specific models were generated in HyperPlan® using planning computed tomography (CT) scans and radiation therapy contours. The original
Made with FlippingBook - Share PDF online